Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFα) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFα agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFα agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
Introduction
. At the ninth month of treatment, significant improvement was noted in disease activity without any adverse effect on kidney function (Table 1 ). In addition, considering ΔASDAS-CRP and ΔASDAS-ESR were 2.75 and 2.89 respectively, the patient achieved "major improvement" (11) . However, the duration of treatment and follow-up was relatively short as compared with ours. In addition, we measured the patients ASDAS, a highly discriminatory tool for assessing disease activity in AS patients as compared with the conventional BASDAI. Thus, as far as we know, this is the first case report about the long term outcome of etanercept treatment for AS patient on PD, using a reliable and discriminative disease activity score.
Summary
Our case suggests that etanercept can be an effective and safe approach to treat AS patients undergoing PD. However, further researches are required to assess the use of etanercept for patients with AS on PD.
